(Kidney Cancer Research Summit – 1st Annual)

Sept 12-13, 2019

Philadelphia, PA

This is what started as a grassroot meeting for all the RCC community focusing on science, ultimate collaboration and inclusiveness. All in the hope of helping our patients live better,  live longer and dream of the cure. Why not?? Isn’t it what we all want if we get this disease ???

I feel this is the beginning of something very very special.

Toni Choueiri, MD  Dana-Farber Cancer Institute

Toni Choueiri, MD, Dana-Farber Cancer Institute

Dear Susan, Bryan, Hans, Toni, steering committee members and all of you who participated in the planning, speaking, or moderating this inaugural meeting:

Kudos to all of you for an engaging and informative meeting!

To Ralph and Brenda: Thank you for inspiring us and reminding us of the urgency of our research. This is what all of our work is about, making a difference in the lives of patients with RCC, that they may have life and have it abundantly.

Nizar Tannir, MD

MD Anderson Cancer Center

Nizar Tannir, MD, MD Anderson Cancer Center

Kidney Cancer Coalition & KCAN: Stronger Together

Kidney Cancer Coalition and KCAN have joined forces to accelerate life-saving research and clinical trials for kidney cancer.

The union of these two complementary charitable organizations represents a promising step for the kidney cancer community.

Together, we’ll be known as KidneyCan—carrying that name forward while embracing the “CAN” legacy to reinforce our driven and optimistic vision for our role in the fight against this deadly disease.

Battling what is among the most prevalent forms of cancer among men (#6) and women (#10) in the U.S.*—yet still among the most under-funded and under-recognized cancers— patients, caregivers, advocates, and scientists are in dire need of greater awareness, funding, and action. That is our focus.

As one, we bring proven effectiveness at raising money for research—from grassroots efforts, to private contributions and corporate grants, up through substantial federal funding. Our impact in just four combined years of existence includes:

Spearheading efforts to initiate a $45 million Congressional grant program for research;

Raising over $1 million through local efforts and events including our “Rock the Cure” fundraisers, with over $725,000 already put to work in research labs and studies;

Leading the first-ever grassroots-funded clinical trial for kidney cancer; and

Earning a reputation for being extremely efficient at deploying capital directly to clinical and scientific endeavors in pursuit of breakthroughs.

Our founders—Brenda and Ralph Knapp, who started KC Coalition in 2016, and Bryan Lewis, who formed KCAN in 2017—recognized the potential benefits of pooling their strengths and resources. These three devoted leaders have personal experiences with kidney cancer, as patients, caregivers, and advocates. Their commitment to the cause is profound.

Join us Oct. 21-22 for our Community advocacy day on the Hill

Please join us to let your voice be heard

Register HERE today!

In the News

October 2, 2018 / News Page

Nobel Prize Winner 2018 – Immunotherapies

James P. Allison, Ph.D., director of the Cancer Research Institute Scientific Advisory Council, has been awarded the 2018 Nobel Prize in...
Read More
August 8, 2018 / Front News, News Page

Columnist Robert Wilonsky Speaks About His Battle With Cancer

NBC Today Anchor Marc Fein: I had the honor of talking to DMN Dallas City Columnist Robert Wilonsky today about his battle with cancer. He was told he wouldn’t see his son’s next birthday. He did, and his story is remarkable.
Read More
August 6, 2018 / Front News, News Page

Late-stage kidney cancer should have killed me. Thanks to these Dallas doctors, I have a chance

Robert Wilonsky, City Columnist Last summer, my doctor told me I would probably be dead before my son went to...
Read More
July 21, 2018

New Clinical Trial at NIH

Researchers at the National Institutes of Health (NIH) in Bethesda, Maryland, are enrolling patients with kidney cancer (renal cell carcinoma) into a gene therapy study– a new type of precision medicine that genetically reprograms your immune cells to specifically recognize and kill tumor cells.
Read More
July 16, 2018 / News Page

Newly diagnosed metastatic renal cell carcinoma

Daniel George, MD; Toni Choueiri, MD; Walter Stadler, MD; and Richard W. Joseph, MD, discuss data from the CABOSUN trial and the expanded FDA approval for cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma.
Read More
July 16, 2018 / News Page

Cancer patient saved by ‘seek and destroy’ cells

The first NHS cancer patient to benefit from a breakthrough procedure that primes the body’s immune system to ‘seek and destroy’ tumour cells has stunned doctors with his recovery after being given just weeks to live.
Read More
Donate Now!

Since our inception in 2016, we have proudly given over $725,000 to Kidney Cancer Research!


Funded major projects to date include:

  • RADVAX investigator led immunotherapy trial for 25 advanced kidney cancer patients at UT Southwestern combining Nivolumab, Ipilimumab and SBRT.

  • Support of UT Southwestern’s Kidney Cancer Research Program. 1 of only 2 SPOREs (Specialized Programs of Research Excellence) for Kidney Cancer in the US.

 Our primary sources of support are donations from the general public and fundraising.  

Our mission is to abolish Kidney Cancer as a threat to the life and health of patients through advocacy and accelerating research by  offering direct financial support for clinical and laboratory researchers with promising ideas.


Kidney Cancer strikes 63,340/year

14,970/year die from the disease

We want to help change those statistics!

Stay in Touch: Join The Kidney Cancer Coalition Email List!

Please enter your information below: